264 related articles for article (PubMed ID: 21863885)
1. Novel anticancer polymeric conjugates of activated nucleoside analogues.
Senanayake TH; Warren G; Vinogradov SV
Bioconjug Chem; 2011 Oct; 22(10):1983-93. PubMed ID: 21863885
[TBL] [Abstract][Full Text] [Related]
2. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
Senanayake TH; Warren G; Wei X; Vinogradov SV
J Control Release; 2013 Apr; 167(2):200-9. PubMed ID: 23385032
[TBL] [Abstract][Full Text] [Related]
3. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
5. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.
Galmarini CM; Warren G; Kohli E; Zeman A; Mitin A; Vinogradov SV
Mol Cancer Ther; 2008 Oct; 7(10):3373-80. PubMed ID: 18852140
[TBL] [Abstract][Full Text] [Related]
6. Cross-linked polymeric nanogel formulations of 5'-triphosphates of nucleoside analogues: role of the cellular membrane in drug release.
Vinogradov SV; Kohli E; Zeman AD
Mol Pharm; 2005; 2(6):449-61. PubMed ID: 16323952
[TBL] [Abstract][Full Text] [Related]
7. Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates.
Yang Y; Zhou Z; He S; Fan T; Jin Y; Zhu X; Chen C; Zhang ZR; Huang Y
Biomaterials; 2012 Mar; 33(7):2260-71. PubMed ID: 22189143
[TBL] [Abstract][Full Text] [Related]
8. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
Cattaneo-Pangrazzi RM; Schott H; Schwendener RA
Prostate; 2000 Sep; 45(1):8-18. PubMed ID: 10960838
[TBL] [Abstract][Full Text] [Related]
9. Floxuridine Oligomers Activated under Hypoxic Environment.
Morihiro K; Ishinabe T; Takatsu M; Osumi H; Osawa T; Okamoto A
J Am Chem Soc; 2021 Mar; 143(9):3340-3347. PubMed ID: 33648338
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis and Studies on Novel Polymeric Prodrugs of Erlotinib for Colon Drug Delivery.
Kumar S; Sharma B; Bhardwaj TR; Singh RK
Anticancer Agents Med Chem; 2021; 21(3):383-392. PubMed ID: 32781967
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy.
Galmarini CM; Popowycz F; Joseph B
Curr Med Chem; 2008; 15(11):1072-82. PubMed ID: 18473803
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation of poorly soluble drugs in polymer-drug conjugates: effect of dual-drug nanoformulations on cancer therapy.
Senanayake TH; Lu Y; Bohling A; Raja S; Band H; Vinogradov SV
Pharm Res; 2014 Jun; 31(6):1605-15. PubMed ID: 24452808
[TBL] [Abstract][Full Text] [Related]
13. [Antisense oligonucleotides with antitumor activity].
Otvös L; Sági G
Magy Onkol; 2004; 48(3):221-7. PubMed ID: 15520872
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055.
Dueregger A; Guggenberger F; Barthelmes J; Stecher G; Schuh M; Intelmann D; Abel G; Haunschild J; Klocker H; Ramoner R; Sampson N
Phytomedicine; 2013 Nov; 20(14):1306-14. PubMed ID: 23972793
[TBL] [Abstract][Full Text] [Related]
15. N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
Schott H; Goltz D; Schott TC; Jauch C; Schwendener RA
Bioorg Med Chem; 2011 Jun; 19(11):3520-6. PubMed ID: 21536448
[TBL] [Abstract][Full Text] [Related]
16. Sulfonyl-containing nucleoside phosphotriesters and phosphoramidates as novel anticancer prodrugs of 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP).
Sun YW; Chen KM; Kwon CH
Mol Pharm; 2006; 3(2):161-73. PubMed ID: 16579645
[TBL] [Abstract][Full Text] [Related]
17. Aryloxy Pivaloyloxymethyl Prodrugs as Nucleoside Monophosphate Prodrugs.
Alanazi AS; Miccoli A; Mehellou Y
J Med Chem; 2021 Nov; 64(22):16703-16710. PubMed ID: 34734726
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs.
Ludwig PS; Schwendener RA; Schott H
Eur J Med Chem; 2005 May; 40(5):494-504. PubMed ID: 15893023
[TBL] [Abstract][Full Text] [Related]
19. RETRACTED: Enhanced antitumor efficacy of 5-fluorouracil loaded methoxy poly(ethylene glycol)-poly(lactide) nanoparticles for efficient therapy against breast cancer.
Yuan Z; Qu X; Wang Y; Zhang DY; Luo JC; Jia N; Zhang ZT
Colloids Surf B Biointerfaces; 2015 Apr; 128():489-497. PubMed ID: 25779606
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine as an effector in radiation-activated prodrugs.
Shibamoto Y; Mimasu Y; Tachi Y; Hatta H; Nishimoto S
J Chemother; 2002 Aug; 14(4):390-6. PubMed ID: 12420858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
